Oncotarget

Reviews:

Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia

Antonio Sacco, Aldo Roccaro and Irene M. Ghobrial _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2010; 1:578-582. https://doi.org/10.18632/oncotarget.192

Metrics: PDF 2357 views  |   HTML 2565 views  |   ?  


Abstract

Received: October 13, 2010, Accepted: November 17, 2010, Published: November 17, 2010

Tumorigenesis occurs due to synergistic interactions from a complex of signal transduction processes, including multiple onco-proteins and tumor suppressors such as Ras, Myc, PI3K/Akt/mTOR, Her-2/Neu, p53 and PTEN. Specifically, the PI3K/Akt and mTOR pathways have been shown to play a pivotal role on the initiation and progression of malignancies, enhancing cell survival by stimulating cell proliferation, and inhibiting apoptosis. Therefore, it is critical to examine therapeutic agents that explicitly target both the PI3K/Akt and mTOR signaling cascades in diseases, such as Waldenstrom Macroglobulinemia (WM), that harbor activation of the PI3K/Akt pathway. We demonstrated that dual targeting of the PI3K and mTOR pathways by the novel inhibitor NVP-BEZ235, exhibited toxicity on WM cells by directly targeting the tumor clone and indirectly through an effect on the bone marrow milieu. These findings suggest that dual targeting of the PI3K and mTOR pathways is a better modality of targeted therapy for tumors that harbor activation of the PI3K/mTOR pathways, such as in WM.

 


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 192